Reviva to Participate in the Citizens Life Sciences Conference
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a fireside chat format.
The presentation is scheduled for Thursday, May 8, 2025, at 10:30 a.m. ET. Reviva focuses on developing therapies for:
- Central nervous system (CNS) diseases
- Inflammatory conditions
- Cardiometabolic diseases
The company aims to address unmet medical needs in these therapeutic areas. A webcast link has been provided for interested parties to access the presentation.
Positive
- Late-stage pharmaceutical company status indicates advanced product pipeline
- Diversified therapeutic focus across CNS, inflammatory and cardiometabolic diseases
Negative
- None.
News Market Reaction – RVPH
In the trading session that priced this news, RVPH gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY.
Citizens Life Sciences Conference
Format: Corporate Update / Fireside Chat
Date: Thursday, May 8, 2025
Time: 10:30 a.m. ET
Location: New York, NY
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
